Issue 3 2021

CEO MONTHLY / ISSUE 3 2021 21 , Committed To Innovation Established in 2004, Lexaria Bioscience Corp has become the global leader in enhancing the speed and efficiency of orally delivered molecules and drugs. To begin, Chris provides a brief overview of the firm and offers more insight into its clientele. “Lexaria operate four subsidiary companies to focus on its different commercial opportunities in their respective industries. Lexaria Pharma Corp investigates new products for hypertension, anti-viral treatments and other drug classes, Lexaria Nicotine Corp investigates oral non-combusted tobacco-derived nicotine product formats, Lexaria Hemp Corp pursues B2B opportunities with cannabinoids, and finally by operating a modern laboratory, Lexaria Canpharm Corp are experts in developing novel psychotropic cannabinoid formulations.” To open some of the doors which were previously closed, Lexaria remain committed to innovation and in particular the development of its unique drug delivery technology DehydraTECH™. “DehydraTECH™ has been laboratory and market proven to enhance the performance of several categories of fat- soluble active molecules and drugs” Chris highlights. “With the technology promoting healthy administrative methods, lower overall dosing, and a higher effectiveness of ingestible drugs, compounds processed using DehydraTECH™ Located in Kelowna, Lexaria Bioscience Corp has developed its technology for the improved taste, rapidity, and delivery of bioactive compounds. Following his well-deserved success in the Global CEO Excellence Awards 2020, we got in touchwith Chris Bunka to find out more. Jun20138 become masked to oral and olfactory receptors, making them essentially flavourless and odourless. Naturally, this can be a notable benefit in both non-pharmaceutical and pharmaceutical applications of the technology since DehydraTECH™ formulations do not require unwanted sweeteners or chemical masking agents for flavour and odour blocking. This allows manufacturers to create low-sugar products with fewer calories, while also avoiding the use of excessive artificial sweeteners.” Remaining at the forefront of its industry is of utmost importance to Lexaria, and in addition to technology, the firm produce industry-leading research to support its delivery methods, as Chris goes on to explain. “In 2018, we completed a successful human clinical study evidencing statistically significant gains in cannabidiol delivery and performance, and with additional in vivo animal and/or human studies at various stages of development and execution.” Although Lexaria have made great progress since forming, none of this would have been possible without the efforts of its team members, as Chris points out. “The firm’s talented and dedicated team have been instrumental in supporting Lexaria’s development and growth. For example, our consulting team includes industry leaders, research scientists, clinicians, and analytical chemists. Without the knowledge and insight provided by these key figures our services would suffer as a result.” Looking ahead to what the future holds for the firm, Chris and the team at Lexaria have a number of exciting plans lined up in the pipeline for the years to come. For instance, one of their main goals in to maintain the reputation they have proudly built since their inception. Ultimately, the Lexaria workforce will continue to work hard to ensure that they not only meet their clients’ requirements but exceed their expectations. Company: Lexaria Bioscience Corp Contact: Chris Bunka Web: www.lexariabioscience.com